Kilpatrick Townsend & Stockton LLP
Silencing of CSN5 gene expression using interfering RNA
The present invention provides compositions comprising nucleic acids that target CSN5 gene expression and methods of using such compositions to silence CSN5 gene expression. More particularly, the present invention provides unmodified and chemically modified interfering RNA molecules which silence CSN5 gene expression and methods of use thereof, e.g., for treating cell proliferative disorders such as cancer. The present invention also provides nucleic acid-lipid particles that target CSN5 gene expression comprising an interfering RNA molecule, a cationic lipid, a non-cationic lipid, and optionally a conjugated lipid that inhibits aggregation of particles.
Protiva Biotherapeutics, Inc. The United States of America, as represented by the Secretary, Department of Health and Human Services
C A C C A
C12N A61K C12N C12N A61P
inventional additional inventional additional inventional
Snorri S. Ian Yun-Han Adam
Thorgeirsson MacLachlan Lee Judge